25 May 2013
Keywords: study, questions, safety, pfizer, bextra, there, been
Article | 15 November 2004
There have been further concerns raised over the safety of the COX-2 inhibitor class at the American Heart Association meeting ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 November 2004
8 November 2004
24 May 2013
© 2013 thepharmaletter.com